Greetings From the Editor of *Clinical Thyroidology*

DEAR COLLEAGUES,

It has been a season of several important endocrine annual scientific meetings. I am glad to share that *Clinical Thyroidology* and the ATA were at the recent Endocrine Society, American Association of Clinical Endocrinologists (AACE), and American Association of Endocrine Surgeons (AAES) annual meetings to hear about the groundbreaking thyroid research presented at these conferences. We plan to review and comment on many of the findings and papers presented at these meetings in upcoming issues of the journal.

In this month's issue, Dr. Trevor Angell reviews the recently published provocative paper examining the role of thyroidectomy in patients with Hashimoto's disease who have persistent symptoms suggestive of thyroid dysfunction. On the topic of hyperthyroidism, Dr. Mary Samuels reviews the role of selenium supplementation in the prevention of Graves' disease, while Drs. Suneeta Ganji and David Cooper comment on a paper summarizing the long-term use of methimazole for autonomous thyroid nodules. Dr. Tim Korevaar reviews the long-awaited TABLET trial, which reports the obstetric effects of levothyroxine on euthyroid antibody-positive women during pregnancy, while Dr. Elizabeth Pearce reviews a meta-analysis of three large European pregnancy cohorts on the associations between mild-to-moderate maternal iodine deficiency and childhood neurodevelopment.

In the areas of thyroid nodules and thyroid cancer, Dr. Stephanie Fish comments on a paper reporting the performance characteristics of the Afirma GSC compared to those of the Afirma GEC in cytologically indeterminate thyroid nodules. Dr. Tracy Wang examines the clinical factors associated with lower quality-of-life scores in patients with thyroid cancer, and Dr. Daniel Toft reviews the weight of multifocality in papillary thyroid cancer with regard to the extent of disease at initial presentation. Finally, Dr. Maria

Papaleontiou discusses a paper examining the relationships between obesity phenotypes and thyroid cancer, and Dr. Douglas Van Nostrand presents his viewpoint on the role of BRAF and/or MEK inhibitors in resensitizing BRAF-mutated radioiodine refractory differentiated thyroid cancers to iodine.

I invite you all to follow us through our social media channels listed below. They are wonderful ways to discuss the research reviewed in the journal with others representing a very wide range of backgrounds. I am personally thrilled to have met so many of you through social media! Check us out at:

Twitter: [@clinicalthyroid](https://twitter.com/clinicalthyroid)

Facebook: <https://www.facebook.com/ThyroidAssociation>

LinkedIn: <https://www.linkedin.com/company/american-thyroid-association>

Youtube: <https://www.youtube.com/user/thyroidorg>

Finally, thank you for your continued interest in and readership of the journal. I hope that you find the topics we cover to be directly relevant and impactful to the care of your patients. Please feel free to send me any questions or comments at clinicalthyroidology@thyroid.org.

Warm regards,

Angela M. Leung, MD, MSc
Editor-in-Chief, *Clinical Thyroidology*